|
 |
European Pharmaceutical Contractor
|
Clinical development accounts for 60 to 70 per cent of the time needed to get a new chemical entity (NCE) to market and over the years, conscientious clinical teams have done all they can to reduce the risk of study delays and to minimise the impact of any setbacks. And indeed there have been considerable successes along the way. Since the 1980s, pharma companies have been able to complement their own resources by calling upon contract research organisations (CROs) to avoid delays caused by lack of resources or inexperience in a particular therapeutic area. More recently, technology and centralised dispatch systems have been used to ensure the timely, reliable distribution of clinical trial supplies to sites actively recruiting patients, while electronic data capture offers the potential to speed up data management and create a real-time study database.
Delay, What Delay?
As each source of delay is identified and overcome, it is hard to ignore the fact that many studies in Western Europe are delayed by poor patient recruitment. Most professionals involved in clinical trials will have experienced this problem first-hand and the published evidence for it is growing. Last year, the British Medical Journal reported that Britain has a poor patient recruitment record, achieving less than 80 per cent of the patients promised (1).
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
PAT and Quality by Design for Biopharmaceuticals
25-26 May 2010, London, UK
Pharma IQ is delighted to announce the inaugural PAT and quality by design for biopharmaceuticals, being held in London on the 25th-26th May 2010. With PAT and quality by design techniques now established within the small molecules field the focus is shifting to application within the biopharmaceuticals arena, with key regulatory bodies such as the FDA and EMEA actively getting involved I pilot case studies. This event will bring together professionals specifically tasked with implementing PAT and QbD tools and techniques specifically within the bioprocess and bioproduction area.
More info >> |
|
 |
News and Press Releases |
 |
Manufacturers Opting for OPTIMA Performance
Over the past 15 years Optima Control Solutions Ltd (OCS) has developed an unrivalled reputation for designing, building and commissioning high-quality drive control systems and through its sister company, Infoserve365, is also now a UK leader in managed data collection and analysis
More info >> |
|
 |
